A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Ubiquitin and SUMO conjugation as biomarkers of Acute Myeloid Leukemias response to chemotherapies
[article]
2019
bioRxiv
pre-print
Ubiquitin and the ubiquitin-like SUMO are covalently conjugated to thousands of proteins to modulate their function and fate. Many of the enzymes involved in their conjugation are dysregulated in cancers and involved in cancer cells response to therapies. We describe here the identification of biomarkers of the activity of these enzymes and their use to predict Acute Myeloid Leukemias (AML) response to standard chemotherapy (daunorubicine-DNR and cytarabine-Ara-C). We compared the ability of
doi:10.1101/825182
fatcat:ztm4dgqtbzabbkyu5squ2ds2m4